TISIDB

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Lateral cell membrane Single-pass type I membrane protein Cell junction, tight junction Note=Colocalizes with CLDN7 at the lateral cell membrane and tight junction.
Domain	PF00086 Thyroglobulin type-1 repeat
Function	May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001657 ureteric bud development GO:0001822 kidney development GO:0001823 mesonephros development GO:0007162 negative regulation of cell adhesion GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0023019 signal transduction involved in regulation of gene expression GO:0040017 positive regulation of locomotion GO:0044331 cell-cell adhesion mediated by cadherin GO:0048863 stem cell differentiation GO:0051272 positive regulation of cellular component movement GO:0072001 renal system development GO:0072073 kidney epithelium development GO:0072089 stem cell proliferation GO:0072091 regulation of stem cell proliferation GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:2000047 regulation of cell-cell adhesion mediated by cadherin GO:2000048 negative regulation of cell-cell adhesion mediated by cadherin GO:2000147 positive regulation of cell motility GO:2000648 positive regulation of stem cell proliferation
Molecular Function	GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005923 bicellular tight junction GO:0016323 basolateral plasma membrane GO:0016324 apical plasma membrane GO:0016328 lateral plasma membrane GO:0043296 apical junction complex GO:0045177 apical part of cell GO:0070160 occluding junction

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EPCAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between EPCAM and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27697766	Acute Myeloid Leukemia	Inhibit immunity; immunotherapy target	In this study, we compared gene expression patterns of acute myeloid leukemia (AML) and normal bone marrow samples and found that epithelial cell adhesion molecule (EpCAM) is frequently overexpressed in patients with AML, with EpCAM+leukemic cells exhibiting enhanced chemoresistance and oncogenesis. Finally, EpCAM antibody treatment depleted AML in subcutaneous, disseminated, and intramedullary engrafted mice. In summary, EpCAM exhibits promise as a novel target for the treatment of leukemia.
16404366	Colon carcinoma; Gastric carcinoma; Prostate carcinoma; Lung carcinoma	Inhibit immunity	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
19188665	Colon Carcinoma	Inhibit immunity (T cell function)	Here, we analyzed T-cell immune responses to the epithelial cell adhesion molecule (EpCAM), one of the most common tumor-associated antigens (TAA) serving as immune target in colon cancer patients. Th-cell priming against EpCAM inevitably resulted in interleukin-4 (IL-4)-dominated Th2 responses, even under most stringent Th1-inducing conditions. These EpCAM-reactive Th2 cells rather promoted growth of EpCAM-expressing tumors.
24980949	carcinoma	Inhibit immunity	In conclusion, our data suggest that anti-EpCAM(scFv)-MAP may be of therapeutic value for the targeted elimination of EpCAM(+) carcinomas.
20053761	Endometrial Serous Adenocarcinoma	Immunotherapy target	Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). EpCAM-positive cell lines were found highly sensitive to MT201-mediated antibody-dependent cellular cytotoxicity in vitro, whereas primary USPC cell lines were resistant to natural killer cell-dependent cytotoxicity.

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EPCAM in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EPCAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.235	0.627
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.121	0.146
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.419	0.536
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.909	0.115
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.534	0.745
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.392	0.542
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.255	0.745
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.807	0.478
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.355	0.268
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.227	0.9
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.807	0.757
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.26	0.177

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EPCAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPCAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPCAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPCAM. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPCAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EPCAM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EPCAM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EPCAM
Name	epithelial cell adhesion molecule
Aliases	Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EPCAM collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting EPCAM.

ID	Name	Drug Type	Targets	#Targets
DB05319	oportuzumab monatox	Biotech	EPCAM	1
DB05831	ING-1	Small Molecule	EPCAM	1
DB06607	Catumaxomab	Biotech	CD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B	6
DB09336	Technetium Tc-99m nofetumomab merpentan	Small Molecule	EPCAM, MS4A1	2
DB11075	Hypromellose	Small Molecule	EPCAM	1

Browse EPCAM